Clinical Trial Update: Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a conditioning regimen of bortezomib followed by high-dose melphalan and bortezomib for tandem stem cell transplants in multiple myelom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Leukemia

Drugs mentioned

• Bortezomib (bortezomib)
• Melphalan (Melphalan)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Multiple Myeloma, Plasma Cell Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2013-10-24